1. Pink Sheet
  2. >>Geography
  3. >>International

ICH Explains How To Assess Mutagenic Impurities To Limit Carcinogenic Risk

 
• By Neena Brizmohun

New guidance that the International Council for Harmonisation says provides a practical framework for identifying, categorizing, qualifying and controlling mutagenic impurities to limit potential carcinogenic risk is now ready for implementation in the ICH regions.

drug development
A new guidance deals with assessing the mutagenic potential of impurities • Source: Shutterstock

Synthetic impurities, degradation products and considerations for clinical development are among a raft of topics discussed in a newly adopted guideline by the International Council for Harmonisation on the assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.

The ICH has also adopted an addendum to accompany the guideline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.